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Abstract
Background: Adiponectin exerts several beneficial cardiovascular effects, however their specific molecular
mechanisms require additional understanding. This study investigated the mechanisms of adiponectin action in the
heart during high fat diet (HFD) feeding or in palmitate (PA) treated H9c2 cardiomyoblasts.
Methods: 6-week-old male adiponectin knock out (Ad-KO) mice were fed chow or 60% HFD for 6 weeks then
received saline or recombinant adiponectin (3μg/g body weight) for an additional 2 weeks. After acute insulin
stimulation (4 U/kg), tissue and serum samples were collected for analysis. H9c2 cardiomyocytes were treated ±0.1mM
PA, the adiponectin receptor agonist AdipoRon, or the antioxidant MnTBAP then assays to analyze reactive oxygen
species (ROS) production and cell death were conducted. To specifically determine the mechanistic role of S1P, gain
and loss of function studies were conducted with adding S1P to cells or the inhibitors THI and SKI-II, respectively.
Results: HFD feeding induced cardiac insulin resistance in Ad-KO mice, which was reversed following replenishment of
normal circulating adiponectin levels. In addition, myocardial total triglyceride was elevated by HFD and lipidomic
analysis showed increased levels of ceramides and sphingosine-1-phosphate (S1P), with only the latter being corrected
by adiponectin administration. Similarly, treatment of H9C2 cardiomyoblasts with PA led to a significant increase of
intracellular S1P but not in conditioned media whereas AdipoRon significantly increased S1P production and secretion
from cells. AdipoRon or the antioxidant MnTBAP significantly reduced PA-induced cell death. Gain and loss of function
studies suggested S1P secretion and autocrine receptor activation mediated the effect of AdipoRon to attenuate PA-
induced ROS production and cell death.
Conclusion: Our data establish adiponectin signaling-mediated increase in S1P secretion as a mechanism via which
HFD or PA induced cardiomyocyte lipotoxicity, leading to insulin resistance and cell death, is attenuated.
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Background
Obesity is a major risk factor for the development of car-
diovascular diseases, including heart failure [1, 2]. Previous
studies have identified many contributors to the initiation
and progression of cardiac remodeling in obesity including
lipotoxicity, hypoadiponectinemia, and insulin resistance
[3–5]. Lipotoxicity is a consequence of a high-fat diet
(HFD), resulting in elevated circulating free fatty acids and
can lead to insulin resistance and metabolic dysfunction
[6]. Altered cardiac energy metabolism is well known as
one of the first observable cardiac remodeling events dur-
ing development of heart failure [7]. Metabolic changes
include less mitochondrial oxidative metabolism, elevated
glycolysis, as well as uncoupling between glycolysis and
glucose oxidation. Collectively these result in metabolic
inefficiency leading to cardiac contractile dysfunction.
Insulin resistance is well characterized as a major contribu-
tor to cardiac dysfunction via metabolic and other cellular
consequences [8]. Accordingly, metabolic modulation, such
as via insulin sensitization, remains a priority target for
new therapeutics [9]. In addition, cardiomyocyte apoptosis
is another important consequence of lipotoxicity which
contributes to the development of heart failure [10, 11].
Circulating adiponectin (Ad) levels correlate nega-
tively with visceral obesity, diabetes and cardiovascular
diseases [5]. Adiponectin has been shown to have bene-
ficial cardioprotective effects, including direct meta-
bolic, insulin-sensitizing, and anti-apoptotic effects [5].
Ad acts via binding to Ad receptor 1 (AdipoR1) and 2
(AdipoR2) [12]. Early studies identified two Ad recep-
tor adapter proteins adaptor protein, phosphotyrosine
interacting with PH domain and leucine zipper 1
(APPL1) and 2 (APPL2) which regulate the downstream
activation of effectors such as AMP-activated protein kin-
ase (AMPK) [13], leading to increased glucose uptake and
lipid uptake and oxidation. Indeed, transgenic mice
overexpressing APPL1 were protected from HFD-induced
cardiomyopathy [14]. Insightful studies have identified
AdipoR-mediated activation of ceramidase activity [15] as
leading to enhanced ceramide conversion to S1P. This
direct link of lipid signaling and metabolism has subse-
quently been shown to have important metabolic con-
sequences in glucose and lipid metabolism [16, 17].
Since Ad can elicit various cardioprotective cellular ef-
fects, there has been great interest within the pharmaceut-
ical industry to identify small molecules which act as
AdipoR agonists [18, 19]. One such compound, Adi-
poRon, was identified and shown to mimic Ad signaling
in various cell types and animal models [20, 21]. However,
the exact mechanisms via which Ad or AdipoRon protect
the heart during diet-induced obesity and cardiomyocytes
from lipotoxic conditions require further research to pro-
vide additional insight. Here we used Ad knockout
(Ad-KO) mice to examine cardiac insulin sensitivity and
lipid metabolism after HFD feeding. We also examined
the role of Ad in correcting HFD-induced abnormalities
in lipid metabolism and insulin action by replenishing
normal circulating Ad levels in one group of Ad-KO mice.
We then studied potential cellular mechanisms using a
model of lipid-induced oxidative stress and cell death in
H9c2 cardiomyoblasts, with or without AdipoRon treat-
ment. Our data provide new insights into the mechanisms
of HFD induced cell death and further highlight the role
of Ad and S1P in these mechanisms.
Methods
Materials
Insulin (Humulin R) was purchased from Eli Lilly (To-
ronto, Canada). Polyclonal phosphospecific antibodies to
Akt (T308&S473), total Akt, pAMPK Thr172, AMPK,
GAPDH and horseradish peroxidase (HRP)-conjugated
anti-rabbit-IgG were from Cell Signaling Technology
(Beverly, MA), while polyclonal phospho-specific anti-
bodies to AdipoR1 and AdipoR2 were a kind gift from
Dr’s Tony Clementz and Jan Oscarsson (Astra Zeneca,
Sweden), and APPL1, APPL2 antibodies from Antibody
Immunoassay Services (Hong Kong). Polyvinylidene
difluoride (PVDF) membrane was from Bio-Rad (Burlington,
ON) and chemiluminescence reagent plus was from
PerkinElmer (Boston, MA). 2-acetyl-5-tetrahydroxybu-
tyl imidazole (THI), an inhibitor of sphingosine-1-phos-
phate lyase, and 4-[4-(4-chloro-phenyl)-thiazol-2-yla
mino]-phenol (SKI-II), an inhibitor of sphingosine kinase,
were purchased from Cayman Chemical (Ann Arbor, MI).
S1P and MnTBAP were purchased from Sigma Aldrich
(St. Louis, MI). All other reagents and chemicals used
were of the highest purity available.
Experimental animals
Male Ad-KO mice [22] bred and genotyped in-house
were randomly allocated to experimental groups as indi-
cated. At 6 weeks of age, animals were fed either regular
chow diet or 60% high-fat diet (HFD) for a period of 6
weeks. At the end of the 6 weeks, chow and HFD-fed
Ad-KO animals received either saline or Adiponectin
(3 μg/g body weight) twice daily for an additional 2
weeks via intraperitoneal injection. This approach has
been optimized as the amount required to restore circu-
lating adiponectin levels to within the normal range
[23–25]. Ad was prepared in saline as described previ-
ously [26]. At the end of the treatment, animals were
starved for 5–6 h and were then subjected to acute insu-
lin stimulation by a bolus insulin (4 U/kg body weight)
injection via tail vein; tissues were harvested 15 min
later. Tissue samples were collected and snap frozen in
liquid nitrogen (N2) and kept together with serum sam-
ples from the same animals at − 80 °C until analysis.
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Heart homogenization and analysis
Whole hearts were snap frozen in liquid nitrogen and
prepared for analysis as described previously [27].
Tissue-specific TG and ATP content were analyzed
using the colorimetric Triglyceride Quantification and
ATP Assay Kit, whereas lactate content was evaluated
using the Lactate Colorimetric Assay Kit II purchased
from Biovision (California, USA).
Preparation of heart homogenates, cell lysates, and
Western blotting
All tissue and cell samples were prepared as described
previously [28] and primary antibodies [phospho-Akt
(S473&T308), total Akt, AdipoR1, AdipoR2, APPL1,
APPL2 and GAPDH] were incubated for 1 h at a dilution
of 1:1000. Membranes were then washed four times with
1x wash buffer for 15min each at room temperature and
incubated with the appropriate HRP-coupled secondary
antibody (1,10,000). Membranes were washed five times
with 1x wash buffer for 10 min each and proteins visu-
alized using enhanced chemiluminescence. Quantita-
tion of each specific protein band was then determined
via densitometric scanning with correction for the re-
spective loading control.
Lipidomic analysis of myocardial lipids
Cardiac diacylglycerols (DAGs) were measured by LC-MS-
MS with atmospheric pressure chemical ionization (APCI)
source and measured species were 16:0, 18:1, 18:0–20:4,
16:0–18:1, and 18:0–18:2 DAGs using HPLC 1200 series
(Aglient Technologies, Santa Clara, CA, USA) with a
Gemini C6-phenyl column (50 × 2.0 mm i.d., 3 μm, Phe-
nomenex, Torrance, CA, USA) and Triple Quadrupole/Ion
Trap mass spectrometer equipped with Heated Nebulizer
interfaces (4000 QTrap, ABSciex, Foster city, CA) as de-
scribed previously [29]. Ceramides with various acyl chains
(C14:0, C16:0, C18:0, C18:1, C20:0, C24:0, C24:1) were sep-
arated by HPLC with a C18 column (XTerra C18, 3.5m,
2.150mm) and ionized in positive electrospray ionization
mode as described previously [30]. Sphingolipid metabolites
were monitored for multiple reaction monitoring (MRM)
quantification by a bench-top tandem mass spectrometer
with an electrospray ionization source.
S1P ELISA kits
For both heart and serum samples, the level of S1P was
measured using an ELISA from Echelon Biosciences
(Salt Lake City, UT), following manufacturers instruc-
tions. As this kit is not suitable for detection for S1P
from rat based samples, for cell culture experiments with
H9c2 cells a rat-specific S1P ELISA kit was purchased
and conducted following manufactures instructions from
MyBioSource (San Diego, CA).
Fatty acid preparation
A Stock solution of palmitate (PA) was prepared by dis-
solution in 70% ethanol to create a 100 mM concentra-
tion stock. This solution was then diluted with 8%
bovine serum albumin (BSA) in PBS to make 5 mM
working solutions. A control BSA solution was prepared
by using an equal amount of 70% ethanol to that of the
PA solution. Conjugation was completed at 37 °C with
shaking for 4 h. Finally, the 5 mM stock solutions were
sterile filtered into aliquots and stored at -80 °C.
H9c2 cardiomyocyte experiments and analysis
H9c2 cells were plated in a 96 well plate (50,000 cells/ml)
and left overnight. Cells were then incubated with 0.5%
BSA for 4 h. Following which 0.1 or 0.25mM concentra-
tions of either BSA or PA were added. Additional a subset
of cells was then treated with either 35 μM AdipoRon,
100 μM MnTBAP, 5 μM SKI-II, 5 μM THI, or 2.5 μM S1P
as indicated. For the DCF-DA assay cells were first washed
with PBS++ and then incubated with 20 μM DCF-DA for
30min. Cells were then washed twice in PBS++. Following
which fluorescence was measured at 488 nm excitation
and 525 nm emission.
The LDH release assay was conducted using a kit fol-
lowing manufacturers instructions (G-Biosciences, St.
Louis, MO). The Trypan Blue plate based assay was con-
ducted according to a previously published protocol
[31]. Briefly trypan blue was added to the wells at a final
concentration of 0.05% and incubated for 15 min. Fol-
lowing which the wells were washed gently using 300ul
PBS++ three times. Then 100ul of a 1% SDS solution
was added to each well and incubated on the shaker for
5 min to ensure lysis. The plate was then read at 590
nm. The Caspase 3/7 assay was conducted using the
CellEvent Caspase 3/7 Green Detection reagent manu-
facturers instructions (Thermofisher, Waltham, MA).
Statistical analysis
All data were calculated as means ± SEM and further
analyzed using one-way ANOVA or Welch’s two-sample
t-tests as appropriate. Differences were considered statis-
tically significant at P < 0.05 and for lipidomics were fur-
ther stratified to P < 0.01 and P < 0.001 respectively.
Results
Replenishment of adiponectin in ad-KO mice corrects
high fat diet-induced cardiac insulin resistance
Insulin-stimulated signaling (Akt T308 and S473) was ex-
amined in the heart of Ad-KO mice fed chow or HFD for
6 weeks and in the latter group also after administration
of Ad for an additional 2 weeks (Fig. 1a). Ad-KO mice on
HFD had significantly reduced insulin sensitivity com-
pared to chow-fed Ad-KO mice, which was reversed fol-
lowing treatment with Ad (Fig. 1a). In addition, restoring
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Fig. 1 Adiponectin treatment reverses diet-induced cardiomyocyte insulin resistance. Adiponectin knockout (Ad-KO) mice were fed either commercial
chow (Chow) or 60% high fat diet (HFD) diet at the age of 6 weeks for a period of 6 weeks. After 6 weeks of HF diet, Ad-KO mice were treated with
either saline or Ad at a dosage of 3 μg/g body weight twice a day for additional 2 weeks via intraperitoneal injection. Insulin signaling was assessed 15
min after a bolus injection of insulin (4 U/kg body weight) via the tail vein upon 4–5 h of fasting. a Representative western blot images and
quantitative analysis of a) insulin-stimulated phosphorylation of Akt, at both Thr308 and Ser473 compared to total Akt and b) p-AMPK (thr172) over
total AMPK. c Triglyceride, d ATP and e) Lactate content were analyzed in whole heart tissue collected from animals. f Expression levels of AdipoR1,
AdipoR2, APPL1 and APPL2 from heart tissues collected from Ad-KO mice with or without additional adiponectin treatment upon chow or HFD.
GAPDH was used as loading control. Data represent mean ± SEM; *P < 0.05 vs Chow, #P < 0.05 vs 60% HFD, n = 4–5
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Ad levels in Ad-KO mice led to an increase in phospho-
AMPK levels similar to that observed in chow-fed Ad-KO
controls (Fig. 1b). Furthermore, restoring normal cir-
culating Ad levels lowered myocardial triglyceride
content (Fig. 1c), and increased ATP and lactate con-
tent (Fig. 1d&e). These Ad-induced changes were not
correlated with any significant changes in AdipoR1
the adaptor proteins APPL1 and APPL2, however,
there was a reduction in AdipoR2 protein levels after
administration of Ad (Fig. 1f ).
Lipidomic analysis of metabolite profiles in ad-KO mice
fed chow or HFD with and without adiponectin
replenishment
Lipidomic analysis was performed to profile specific lipid
species in hearts isolated from Ad-KO mice after 6
weeks feeding with chow or HFD ±Ad replenishment
for 2 weeks. In Fig. 2a, the left side vertical axis repre-
sents data comparing changes in Ad-KO mice on HFD
versus chow diet (decrease to left and increase to right).
HFD significantly increased the production of total cera-
mides, in particular several distinct ceramide species
(16:0, 18:1, 18:0 and 20:0) were most significantly in-
creased (Fig. 2a). Total and 18:1 sphingomyelin was also
increased by HFD (Fig. 2a). Somewhat surprisingly, these
were not significantly altered after Ad replenishment as
shown on Fig. 2a right side vertical axis. Notably, a de-
creased 16:0 dihydroceramide level was observed in re-
sponse to HFD and this was largely reversed by Ad (Fig. 2a).
Importantly, sphingosine-1-phosphate (S1P) content in the
heart was increased by HFD and significantly reversed by
Ad (Fig. 2a). To gain further insight into these changes, we
next examined S1P in serum and myocardium of these mice
using an ELISA-based approach and found similar observa-
tions in heart tissue, where there was an increased in intra-
cellular S1P (Fig. 2b) whilst there were no significant
alterations in serum, which represents extracellular levels of
S1P (Fig. 2c). To translate the observations in mice ± HFD
to an in vitro model, we next tested S1P levels by ELISA in
H9c2 cells treated with palmitate (PA). An increase in intra-
cellular (H9c2 cells), but not extracellular (cellular media),
S1P was observed after PA treatment (Fig. 2d&e). Addition
of AdipoRon elicited release of S1P resulting in an increase
in the concentration of S1P in the media (Fig. 2d&e).
Pharmacological manipulation of S1P levels or addition of
AdipoRon regulates ROS production in palmitate-treated
H9c2 cells
Addition of PA to H9c2 cells for 1, 2 and 4 h signifi-
cantly increased levels of reactive oxygen species (ROS),
and this was significantly attenuated by AdipoRon
(Fig. 3a). To determine the role of S1P in the modulation of
the PA-induced ROS response we used sphingosine kinase
inhibitor SKI-II to prevent S1P production in response to
PA, and this significantly reduced ROS production (Fig. 3b).
S1P-lyase catalyzes the irreversible decomposition of S1P to
trans-2-hexadecenal and phosphoethanolamine and its in-
hibitor, THI, caused a small but not significant additive ef-
fect with PA on ROS production (Fig. 3b). In cells treated
with BSA, incubation with SKI-II did not significantly in-
crease ROS production compared to BSA control, however
the addition of THI did significantly increase ROS produc-
tion in comparison to BSA (Fig. 3b). Annexin V staining
showed that there was an increase in apoptosis after treat-
ment with PA that was attenuated by the addition of Adi-
poRon or SKI-II (Fig. 3c). The addition of THI significantly
increased cell death (Fig. 3C). Finally, we used the antioxi-
dant MnTBAP and confirmed that it effectively prevented
PA-induced ROS to a level similar to that observed with
AdipoRon, and not in an additive manner (Fig. 3d). Annexin
V staining after 4 h showed that there was an increase in
apoptosis after treatment with PA that was attenuated by
the addition of AdipoRon or MnTBAP (Fig. 3e).
AdipoRon and pharmacological manipulation of ROS
decreases palmitate-induced cell death
To further confirm that cell death is a major consequence
of elevated ROS in PA-treated H9c2 cells, we measured this
by LDH (Fig. 4a), MTT (Fig. 4b) and trypan blue assays
(Fig. 4c). AdipoRon alone caused no significant change in
cell death assessed using LDH and MTT assays (Fig. 4a, b)
and a small but significant increase when trypan blue assay
was used (Fig. 4c). Importantly, AdipoRon significantly at-
tenuated PA-induced cell death (Fig. 4a-c). We next used
the antioxidant MnTBAP and confirmed that it effectively
prevented PA-induced cell death to a level similar to that
observed with AdipoRon (Fig. 4d-f). Across all measures of
PA-induced cell death, there was a similar extent of attenu-
ation by AdipoRon and MnTBAP, and effects of these two
compounds were not additive (Fig. 4d-f).
AdipoRon and pharmacological manipulation of S1P
protect H9c2 cells from palmitate-induced cell death
Similar to incubation with the antioxidant MnTBAP,
various measures of cell death and viability including
LDH assay (Fig. 5a), MTT assay (Fig. 5b), and trypan
blue assay (Fig. 5c) all indicated that SKI-II attenuated
PA-induced cell death. Incubation of BSA treated cells
with SKI-II did not significantly increase cell death com-
pared to cells treated with BSA and AdipoRon. Similarly,
in cells treated with PA, the effect of SKI-II was similar
in magnitude to the effect of AdipoRon and not additive
(Fig. 5a-c). In these assays, THI did not significantly alter
the effect of PA or the ability of AdipoRon to attenuate
PA-induced cell death (Fig. 5a-c). Increasing S1P recep-
tor activation directly through exogenous addition of
S1P, led to a significant reduction in cell death as mea-
sured by LDH (Fig. 5d), MTT (Fig. 5e) and trypan blue
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(Fig. 5f ). Co-incubation with S1P and AdipoRon was not
additive (Fig. 5d-f ).
Discussion
A large body of published literature has demonstrated
the correlations between obesity and myocardial infarc-
tion or development of heart failure. Furthermore, the
underlying mechanisms have been extensively studied
[32, 33]. To do so, high-fat feeding in animal models or
use of high levels of fatty acids in cultured cells have
often been employed. Consequently, numerous cardiac
remodeling processes are now known to occur which in-
crease the risk of myocardial infarction or promote the
progressive development of heart failure [2]. Altered me-
tabolism is often one of the earliest and most important
changes which occurs in obesity [7, 34]. This typically
involves reduced glucose metabolism and an unfavour-
able switch toward over-reliance of fatty acids as a
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substrate for energy production [7, 34]. This may occur
at least in part due to development of insulin resistance,
which is now well established as a major potential con-
tributor to cardiac disease [8]. Another myocardial re-
modeling event which occurs in lipotoxic models, with
or without insulin resistance, is cardiomyocyte cell death
[35]. For many years our lab has studied the cardiopro-
tective actions of Ad and the mechanisms via which Ad
acts [5, 36]. In this study, we used both animal and in
vitro models of lipotoxicity to examine mechanisms
leading to insulin resistance or cell death and how these
are regulated by Ad. The development of cardiac dys-
function in HFD fed mice requires approximately 16
weeks [37, 38], and since the focus of this research was
on evaluating the early mechanisms leading to insulin
resistance and metabolic consequences, 6 weeks was
chosen [2, 14]. Increased accumulation of myocardial
lipids due to HFD, is known to induce cardiac insulin
resistance and metabolic dysfunction [32, 33]. Here we
used this approach in Ad-KO mice and observed ele-
vated total lipid accumulation in Ad-KO after HFD feed-
ing which was correlated with faster and exaggerated
myocardial insulin resistance. Specifically, our lipidomic
analysis of mouse hearts led us to focus on the signifi-
cance of S1P, as discussed below.
Of the specific lipids elevated in high-fat fed Ad-KO
mice, there was a significant increase in total and numer-
ous ceramide species, including 14:0, 16:0, 18:0, 18:1, 20:0.
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However, there was no significant increase in the ceramide
precursor dihydroceramide. Previous research has indi-
cated that both ceramide and dihydroceramide may play a
role in insulin sensitivity [39, 40], and that increased levels
of total dihydroceramide may be potential biomarker for
diabetes susceptibility [41]. These data were expected
based on previous literature [42, 43]. Although our
original hypothesis was that adiponectin would correct
these elevated ceramide levels, this did not occur. Add-
itionally, replenishment of adiponectin slightly increased
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total dihydroceramide, however this increase was not
significant. Here we found a significant increase in S1P,
which is produced from ceramide via ceramidase and
sphingosine kinase activity [44], and this was significantly
reduced when normal circulating Ad levels were restored.
This was a striking observation in light of literature indi-
cating that Ad interaction with its cellular receptors stim-
ulated ceramidase activity and increased S1P production
[15, 45]. Several studies have now shown that S1P medi-
ates the actions of Ad, including SERCA2 activation via
CaMKII-PLB signaling [46]. Although the above reduction
in myocardial S1P after Ad replenishment may at first
appear paradoxical, it is important to note that S1P acts
via secretion and autocrine/paracrine activation of its
cell surface receptors [47]. This was highlighted from
our in vitro studies where we detected an increased S1P
production and secretion in response to AdipoRon, whereas
PA increased intracellular but not extracellular S1P. A limi-
tation of our study is that ceramidase activity was not dir-
ectly measured, but the well established literature showing
adiponectin receptors contain intrinsic ceramidase activity
[45, 48], and the metabolite changes we observed reassure
that adiponectin or AdipoRon do stimulate this enzymatic
activity. We thus decided to next investigate the signifi-
cance of S1P secretion and its promotion by Ad action
in PA-induced lipotoxicity.
To directly study the significance of S1P in this in vitro
model we added S1P to cell culture media to directly
stimulate S1P receptors and used the S1P-lyase inhibitor
THI, both to confer a gain of function. We also used the
sphingosine kinase inhibitor SKI-II to prevent S1P produc-
tion as a loss of function approach. Our data were largely
in agreement with previous research showing that increas-
ing receptor-mediated S1P action through exogenous
addition of S1P led to a decreased PA-induced apoptosis in
primary cardiomyocytes [15]. Indeed, many examples dem-
onstrating beneficial effects of S1P signaling in preventing
cell death in various cells or tissues now exist [49, 50] al-
though, paradoxically, adverse effects have also been re-
ported [51]. Moreover, one previous study showed that PA
increased S1P production in hepatocytes and, unlike our
data in H9c2 cells, it was released into the extracellular
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environment leading to S1P3 receptor activation [52]. An-
other study suggested that S1P activated the S1P2 receptor
to impair hepatocyte insulin signaling [53]. Treatment of
mice with a sphingosine kinase inhibitor significantly de-
creased S1P levels leading to decreased plasma insulin
levels [54]. However, in combination with inhibition of Akt
signaling, increased levels of S1P resulted in decreased in-
sulin production as a result of signaling through S1P2 re-
ceptor [55]. Importantly, overexpression of sphingosine
kinase 1 leads to increased production of S1P and a reduc-
tion in insulin resistance in skeletal muscle after HFD com-
pared to controls [56]. After pharmacologically increasing
intracellular levels of S1P, as does PA, we observed a slight
increase in ROS and apoptosis. This is consistent with pre-
vious findings which showed that increased levels of S1P,
led to increased production of the S1P metabolite
trans-2-hexadecenal which is cytotoxic [57]. This indicates
that increasing production and secretion of S1P or exogen-
ous stimulation of S1P receptors can elicit cardioprotective
effects, whereas intracellular accumulation of S1P can be
lipotoxic. We showed that the addition of AdipoRon alone
increases the production and export of S1P and that Adi-
poRon stimulated the release of intracellular S1P accumu-
lated after PA treatment, thereby mediating protective
effects against ROS production and cell death.
It has been shown that in ischemia-reperfusion ROS
increases levels of ceramide and also leads to the degrad-
ation of sphingosine kinase 1 and 2, enzymes responsible
for the synthesis of S1P [58]. Additionally, previous re-
search has shown that addition of antioxidants such as
MnTBAP or NAC [59, 60] after HFD can reduce insulin
resistance [61, 62]. We used gain and loss of function
studies to show that extracellular S1P is able to attenu-
ate PA-induced ROS and apoptosis, whereas in the ab-
sence of AdipoRon increasing cellular S1P increases
ROS and cell death. Our findings are in agreement with
previously published studies which show that addition of
exogenous S1P protects both isolated hearts, cardiomyo-
cytes, and endothelial cells from ROS induced apoptosis
[63–65]. However, after pharmacologically increasing
levels of S1P, we observed an increase in apoptosis and
cell ROS. This is likely due to an inability of S1P to be
transported out of the cell. This is consistent with previ-
ous findings which showed that increased levels of S1P
led to increased production of the S1P metabolite
trans-2-hexadecenal which has previously been shown to
be cytotoxic, and led to increased levels of ROS. This
was attenuated with the addition of AdipoRon which
caused a release of S1P from the cell and a reduction in
ROS [57]. AdipoRon interacts with the AdipoR1) and 2
(AdipoR2) receptors increasing their intrinsic cerami-
dase activity, activating the S1P conversion pathway and
thereby preventing the buildup of more toxic lipid spe-
cies [15, 45, 66]. While it is expected that adiponectin
will alter insulin sensitivity in HFD fed animals and in car-
diomyocytes [24, 25, 67–69] in the in vitro model insulin
was not added, and thus altered insulin sensitivity is not a
contributing factor to the observed anti-apoptotic effects.
Previous literature has shown that a decrease in anti-
oxidant capacity in the heart, leads to increased ROS
generation and can lead to the development of car-
diomyopathy [70]. We have shown previously that Ad
enhanced antioxidant potential in skeletal muscle to
alleviate lipid-induced ROS production [68].
Conclusions
Using both an in vivo mouse model of HFD in wt or
Ad-KO mice ± Ad replenishment and cultured H9c2 cells
treated with PA ±AdipoRon, our data indicate that S1P is
an important mechanistic route via which adiponectin
may provide cardioprotection via improving cardiomyo-
cyte insulin sensitivity as well as reducing ROS production
and cell death. This data provides further support for a
cardioprotective adiponectin receptor-S1P axis and efforts
to translate these observations for therapeutically benefit
are likely to be of great potential [71–73].
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